Core Insights - Moderna Inc. (MRNA) stock dropped 7% following a report linking the deaths of 25 children to COVID-19 vaccines, resulting in a year-to-date decline of almost 45% [2] - MRNA's performance is being compared to its peers to assess whether its decline is an outlier or part of a broader trend [5] Financial Performance - MRNA's operating margin is -107.1%, the lowest among its peers, while Pfizer (PFE) has an operating margin of 26.1% [8] - MRNA's last-twelve-month revenue growth is -38.8%, underperforming compared to PFE, Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), AbbVie (ABBV), and Amgen (AMGN) [8] - Over the past year, MRNA's stock has decreased by 66.3% and currently trades at a price-to-earnings (P/E) ratio of -3.1, indicating a loss [8] Competitive Context - MRNA has 44 programs, including 26 clinical trials across various therapeutic areas, which include infectious diseases and immuno-oncology [4] - The recent performance of MRNA, including a 12.6% decline over the last month, raises questions about its valuation and fundamentals in comparison to its competitors [5][8]

Core Viewpoint - FuelCell Energy (FCEL) has experienced a significant stock rally, achieving a cumulative gain of 75% over six consecutive days, driven by strong quarterly results and long-term growth potential in the data center market [1][3][4]. Financial Performance - FCEL reported a remarkable 97% year-over-year revenue growth, reaching $46.7 million, indicating strong demand for its products and services [3]. - The company's market capitalization has increased to approximately $207 million, reflecting a gain of about $126 million over the past six days [4]. Market Context - The stock remains 24% below its value at the end of 2024, contrasting with a year-to-date return of 11.9% for the S&P 500 [4]. - The ongoing momentum in FCEL's stock price may signal growing investor confidence, which could lead to further buying activity [4]. Industry Trends - The German government is set to announce a national hydrogen strategy aimed at developing a five-gigawatt electrolysis capacity for green hydrogen by 2030, highlighting the increasing importance of hydrogen in renewable energy plans [3]. - The demand for energy storage solutions, particularly in data centers driven by AI and high-density chips, presents new opportunities for FCEL's modular power block solutions [3].

The Microsoft logo is on their pavilion during the Mobile World Congress 2025 in Barcelona, Spain, on March 5, 2025. (Photo by Joan Cros/NurPhoto via Getty Images)NurPhoto via Getty ImagesMicrosoft's stock (NASDAQ: MSFT) has climbed over 30% in the past six months, driven by strong quarterly results marked by improving revenue growth and expanding margins. However, with the stock now trading at 37 times its trailing earnings, the key question for investors is whether MSFT is still worth buying.We believe MS ...

Arista Networks stock (ANET) fell 8.9% in a single day following the company’s analyst day event, where management outlined its long-term outlook. The networking solutions provider projected sales to grow at a 20% compounded annual rate between fiscal 2023 and fiscal 2026. While this guidance is pretty strong, investors appeared underwhelmed, especially given the stock’s 55% plus rally over the past 12 months. Moreover, the aggressive growth forecasts recently issued by other AI driven companies, including ...

Core Insights - New Mountain Finance (NMFC) has been recognized as a Top 10 dividend-paying financial stock according to Dividend Channel's latest "DividendRank" report [1] - The report highlights NMFC's attractive valuation metrics and strong profitability, with a current share price of $10.47, a price-to-book ratio of 0.9, and an annual dividend yield of 12.23% [1] - In comparison, the average stock in Dividend Channel's coverage yields 3.9% and has a price-to-book ratio of 2.7, indicating NMFC's superior performance [1] Valuation and Profitability - NMFC's annualized dividend is $1.28 per share, paid quarterly, with the next ex-dividend date on 09/16/2025 [2] - The report emphasizes the importance of NMFC's strong quarterly dividend history and favorable long-term growth rates in key fundamental data points [1][2] Investment Appeal - The DividendRank formula used by Dividend Channel aims to identify the most profitable companies trading at attractive valuations, making NMFC a noteworthy candidate for dividend investors [2] - The historical dividend performance of NMFC is considered a critical factor in assessing the sustainability of its current dividend [2]

Markets are waiting on the Federal Reserve to announce a decision on interest rates this Wednesday. (Photo by Win McNamee/Getty Images)Getty ImagesKey Takeaways Fed Rate Cut Expected, Investors Focus On Powell’s Forward Guidance Government Shutdown Risks Rising Despite Markets Showing Limited Fear IPO Strength Signals Appetite, But Valuations Could Become OverextendedStocks posted gains last week with the S&P 500 gaining 0.8% and Nasdaq Composite adding 0.9%. Small caps were relatively unchanged while the D ...

Core Insights - Natera has achieved significant growth since its IPO, with stock prices increasing nearly 10 times from $18 to around $170 and revenues expanding from $190 million to $2 billion, reflecting a 44% revenue growth over the last twelve months [3][11]. Company Overview - Natera specializes in molecular diagnostics, particularly in cancer detection and monitoring, positioning itself as a leader in medical intelligence [4]. - The company's flagship product, Signatera, is a personalized tumor-informed test that utilizes a simple blood draw to detect circulating tumor DNA, revolutionizing cancer monitoring [5][6]. Product and Technology - Natera's technology allows for non-invasive liquid biopsies, providing doctors with critical insights into cancer progression and recurrence risk [6]. - In addition to Signatera, Natera offers Altera for genomic profiling and Empower for hereditary cancer screening, creating a comprehensive suite for cancer care [6]. Market Potential - In the latest quarter, Natera processed over 850,000 tests, generating $546.6 million in revenue, with oncology-related tests growing at 50% year-over-year [9]. - The cell-free DNA testing market is projected to nearly double from $11 billion to around $20 billion in five years, indicating substantial growth potential for Natera [12]. Financial Projections - Natera is expected to sustain 25% annual revenue growth over the next few years, potentially increasing revenue from $1.7 billion last year to approximately $7 billion by 2030 [11]. - If Natera achieves $7 billion in revenue while maintaining a price-to-sales multiple of 13x, the stock price could reach about $700, even with potential multiple compressions [13]. Growth Opportunities - Key areas for growth include expanding the oncology market, scaling internationally, entering adjacent markets, and increasing volume and penetration within existing markets [17]. - Broader insurance coverage and clinical evidence supporting test adoption are critical for expanding market size and pricing power [18]. Competitive Landscape - Natera competes with major players like Roche, Danaher, and Abbott, which have significantly higher revenues, indicating that Natera is still in the early stages of its growth story [12]. - The company must navigate challenges such as reimbursement issues, competitive pressure, regulatory hurdles, and the pace of international adoption [18].

Insider Buying Trends - Insider buying has been below normal in 13 of the past 15 months, with August showing only 26% of purchases compared to sales [3] - Historically, the highest ratio of buys to sells was 2.01 in October 2008 during the Great Recession, indicating that insider buying can signal future recovery [4] Eastman Chemical - Eastman Chemical Co. (EMN) executives, including CEO Mark Costa and CFO McLain William Thomas Jr., made significant purchases of shares on August 27, totaling approximately $502,000 and $252,000 respectively [5] - The stock has fallen 24% this year, impacted by high tariffs on imported materials, yet it has shown profitability for over 30 years [6] - Current valuation is attractive, trading at about nine times earnings and less than one times revenue, suggesting potential for recovery [6] Eli Lilly - Eight executives at Eli Lilly (LLY) bought shares in August, including CEO David Ricks and CFO Lucas Montarce, who spent over $1 million and nearly $495,000 respectively [7] - The stock price has decreased from a high of $942 to around $755, but it trades at a high valuation of 49 times recent earnings and over 12 times revenue, indicating it may be overvalued [8] United Parcel Service - United Parcel Service Inc. (UPS) shares have dropped more than 31% this year, with CEO Carol Tome purchasing over $1 million in August [9] - Despite competitive pressures, UPS maintains a strong return on equity of over 34% and trades for less than 13 times earnings, suggesting potential for future gains [10] First Citizens BancShares - At First Citizens BancShares Inc. (FCNCA), CEO Frank Holding Jr. invested over $1 million in August, alongside four other insiders [11] - The bank has shown improving profits and has consistently achieved a return on assets of 1.0% or better, with the stock trading at a reasonable valuation of 12 times recent earnings [12] Performance of Insider Buying Stocks - Stocks recommended based on insider buying have returned an average of 8.9% over 12 months, underperforming the S&P 500 Total Return Index by 1.8 percentage points [13] - Stocks to avoid despite insider buying have lagged the index by 24 percentage points, while those with ambiguous comments on insider buying have outperformed the index by 14.2 percentage points [14]

CHONGQING, CHINA - JULY 31: In this photo illustration, a person holds a smartphone displaying the logo of Occidental Petroleum Corporation (NYSE: OXY), a major American oil and gas exploration and production company, in front of a screen showing the company's emblem on July 31, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images Occidental Petroleum stock (NYSE: OXY) has faced challenges this year. The stock has declined by 9%, while the S&P 500 rose by 18%. This stark diff ...

(Photo by Kevin Dietsch/Getty Images)Getty ImagesWith the Federal Reserve widely expected to cut rates by 0.25% at its September 16 meeting, attention is turning to where investors can find value in fixed income. Many default to the iShares Core U.S. Aggregate Bond ETF (AGG), which tracks the Bloomberg U.S. Aggregate Bond Index. But just as the S&P 500 captures only part of the equity universe, AGG represents a narrow slice of the bond market, often leaving higher-yielding and diversifying opportunities on ...